EP Patent

EP4699609A2 — Heterocyclic glp-1 agonists

Assigned to Gasherbrum Bio Inc · Expires 2026-02-25 · 0y expired

What this patent protects

This disclosure relates to GLP-1 agonists of Formula I:including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

USPTO Abstract

This disclosure relates to GLP-1 agonists of Formula I:including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP4699609A2
Jurisdiction
EP
Classification
—
Expires
2026-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Gasherbrum Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.